BackOcular Therapeutix Overview
Ocular Therapeutix Inc

Ocular Therapeutix Target Price

Where could OCUL trade next? Consensus target price: $14.

Get informed when a big investor buys or sells

+ Follow

Share Price

$7.14

Average Target Price

$14.0096.1% upside

1 analysts in the last 4 months

High: $14 | Low: $14

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-10-11UBS$1496.1% upsideOpen
2026-06-18H.C. Wainwright$25250.1% upsideOpen
2026-06-18Robert W. Baird$30320.2% upsideOpen
2026-02-05RBC CapitalLisa Walter$30320.2% upsideOpen
2025-12-08H.C. Wainwright$21194.1% upsideOpen
2025-10-08H.C. Wainwright$19166.1% upsideOpen
2025-10-03Piper Sandler$31334.2% upsideOpen
2025-10-03Robert W. BairdColleen Kusy$24236.1% upsideOpen
2025-10-01JMP SecuritiesJonathan Wolleben$29306.2% upsideOpen
2025-03-04JMP Securities$19166.1% upsideOpen
2024-08-08Robert W. BairdColleen Kusy$17138.1% upsideOpen
2024-06-27Piper SandlerBiren Amin$15110.1% upsideOpen
2024-06-14H.C. WainwrightYi Chen$1496.1% upsideOpen
2024-03-12JMP SecuritiesJonathan Wolleben$24236.1% upsideOpen
2022-06-07Piper SandlerJoseph Catanzaro$1040.1% upsideOpen

Ocular Therapeutix (OCUL) FAQ

Ocular Therapeutix's target price stands at $14. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $14 for OCUL implies 96.1% upside versus today's price ($7.14). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Ocular Therapeutix's target price evolved across reporting periods, while the comparison chart places OCUL next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Ocular Therapeutix's reading of $14 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.